BioXcel Therapeutics, Inc. — Director's Dealing 2024

Jun 19, 2024

SEC Form 4/A — Form 4/A

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2023-03-14

Reporting Person: O'Neill Vincent (See Remarks)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3158	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Units	$		Common Stock (0)	0	Direct
Stock Option (Right to Buy)	$		Common Stock (0)	0	Direct

Footnotes

F1: This amendment is being filed to correct the amount previously reported in the Form 4 filed on March 16, 2023 (the "Original Form 4") that inadvertently reported an award of (i) 9,000 restricted stock units ("RSUs") and (ii) options to purchase 32,000 shares of the Issuer's common stock (the "Options"). The Reporting Person was not granted such RSUs and Options and does not beneficially own any shares underlying the awards reported on the Original Form 4.